Additional company office in the Asia Pacific region will showcase Vetter’s expertise and help build and strengthen its business network in China
- New office underscores importance of Chinese market
- Physical presence promotes development of new business in China
- Comprehensive service portfolio supports domestic companies in accessing the global market place
SHANGHAI, CHINA AND RAVENSBURG, GERMANY – Media OutReach – 8 March 2021 – Vetter, one of the global leaders in prefilled drug-delivery systems, today announced the opening of a new business entity in Shanghai, China. The new office, now its fourth in the Asia Pacific (APAC) region, will help increase the visibility of Vetter’s presence in China and underlines its importance as an important strategic market to Vetter. Thus, the office will support customer relations and aid in the development of new business. As the second largest pharmaceutical market and one of the largest in sales growth rate worldwide, China offers a promising injectable pipeline and allows the Contract Development and Manufacturing Organization (CDMO) to offer support to domestic companies that plan on bringing their molecules to the global market. As a strategic partner, Vetter supports its worldwide customer base through every phase of their injectable drug product’s lifecycle, from early development activities to commercial supply up to lifecycle initiatives.
